AU2020331301A1 - Therapeutic antibodies against osteopontin - Google Patents

Therapeutic antibodies against osteopontin Download PDF

Info

Publication number
AU2020331301A1
AU2020331301A1 AU2020331301A AU2020331301A AU2020331301A1 AU 2020331301 A1 AU2020331301 A1 AU 2020331301A1 AU 2020331301 A AU2020331301 A AU 2020331301A AU 2020331301 A AU2020331301 A AU 2020331301A AU 2020331301 A1 AU2020331301 A1 AU 2020331301A1
Authority
AU
Australia
Prior art keywords
seq
antibody
amino acid
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020331301A
Other languages
English (en)
Inventor
Lawrence L. K. Leung
Michael J. Morser
Timothy MYLES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Veterans Affairs
Leland Stanford Junior University
Original Assignee
US Department of Veterans Affairs
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Veterans Affairs, Leland Stanford Junior University filed Critical US Department of Veterans Affairs
Publication of AU2020331301A1 publication Critical patent/AU2020331301A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020331301A 2019-08-09 2020-08-07 Therapeutic antibodies against osteopontin Pending AU2020331301A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962884818P 2019-08-09 2019-08-09
US62/884,818 2019-08-09
PCT/US2020/045466 WO2021030209A1 (en) 2019-08-09 2020-08-07 Therapeutic antibodies against osteopontin

Publications (1)

Publication Number Publication Date
AU2020331301A1 true AU2020331301A1 (en) 2022-02-24

Family

ID=74569814

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020331301A Pending AU2020331301A1 (en) 2019-08-09 2020-08-07 Therapeutic antibodies against osteopontin

Country Status (8)

Country Link
US (2) US12351625B2 (https=)
EP (1) EP4010369A4 (https=)
JP (1) JP7692401B2 (https=)
KR (1) KR20220058554A (https=)
CN (1) CN114867746A (https=)
AU (1) AU2020331301A1 (https=)
CA (1) CA3146092A1 (https=)
WO (1) WO2021030209A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605371B2 (en) 2020-07-31 2026-04-21 The Board Of Trustees Of The Leland Stanford Junior University Combination therapy for cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4256901A (en) * 2000-03-23 2001-10-03 Glaxo Group Limited Method of screening for inhibitors of osteopontin
US20040234524A1 (en) * 2001-04-05 2004-11-25 Toshimitsu Uede Anti-osteopontin antibody and use thereof
US7241873B2 (en) * 2001-09-25 2007-07-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant anti-osteopontin antibody and use thereof
US20050040570A1 (en) * 2002-01-18 2005-02-24 Andreas Asselborn Method and device for determining the characteristics of molten metal
AU2004324192A1 (en) * 2004-10-13 2006-04-27 Genentech, Inc. Method for treating tumors using anti-osteopontin antibodies
EP2077325A4 (en) * 2006-09-11 2012-04-11 Immuno Biological Lab Co Ltd MONOCLONAL ANTIBODY AND ITS USE
JP5339748B2 (ja) 2008-03-11 2013-11-13 国立大学法人北海道大学 ヒトオステオポンチンの活性化を阻害する物質をスクリーニングする方法
CN102597001B (zh) 2009-08-19 2014-07-30 默克专利有限公司 在ffpe材料中用于检测整联蛋白复合体的抗体
EP2914629A1 (en) * 2012-11-05 2015-09-09 MAB Discovery GmbH Method for the production of multispecific antibodies
AU2015279712B2 (en) * 2014-06-26 2021-03-25 Yale University Compositions and methods to regulate renalase in the treatment of diseases and disorders
TW201623329A (zh) * 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
WO2016154623A2 (en) 2015-03-26 2016-09-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-cd133 monoclonal antibodies and related compositions and methods
WO2018083237A1 (en) * 2016-11-03 2018-05-11 Roche Diagnostics Operations Inc. Novel anti-py520-ddr1 antibodies
US20190367602A1 (en) * 2016-12-12 2019-12-05 Synergenics, Llc Novel monoclonal antibodies to osteopontin

Also Published As

Publication number Publication date
EP4010369A1 (en) 2022-06-15
KR20220058554A (ko) 2022-05-09
US20250361293A1 (en) 2025-11-27
CA3146092A1 (en) 2021-02-18
JP2022543657A (ja) 2022-10-13
US12351625B2 (en) 2025-07-08
CN114867746A (zh) 2022-08-05
WO2021030209A1 (en) 2021-02-18
EP4010369A4 (en) 2023-11-22
JP7692401B2 (ja) 2025-06-13
US20220324956A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
CN102947337B (zh) 用于治疗结肠直肠癌的方法
US20200277398A1 (en) Humanized antibodies against ceacam1
KR101820029B1 (ko) 암의 예방 및/또는 치료에서 사용하기 위한 방사성 표지 항체 단편
US10239954B2 (en) Antibodies specific for urokinase-type plasminogen activator and methods of use thereof for treating cancer
KR20180042226A (ko) 암 치료에 사용하기 위한 방사성 표지된 항체 단편
US20250361293A1 (en) Therapeutic Antibodies Against Osteopontin
CN120092020A (zh) Cnx抗原结合分子
US20230364254A1 (en) Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
AU2022328339A1 (en) Methods for treating non-muscle invasive bladder cancer (nmibc) with antibody drug conjugates (adc) that bind to 191p4d12 proteins
HK40070608A (en) Therapeutic antibodies against osteopontin
Cabanillas-Bernal et al. variable single domains (VNARs): broadly neutralizing tools for
EA051680B1 (ru) Способы лечения рака конъюгатами антитело-лекарственное средство (adc), связывающимися с белками 191p4d12
CN119998324A (zh) 浆细胞样树突状细胞的消耗和抑制
HK1252832B (en) Methods for treating colorectal cancer
HK1178918B (en) Methods for treating colorectal cancer
HK1178918A (en) Methods for treating colorectal cancer